A novel MiRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Bell, Erica Hlavin ^a   Kirste, Simon ^a,b   Fleming, Jessica L ^a   Stegmaier, Petra ^a,b   Drendel, Vanessa ^b   Mo, Xiaokui ^c   Ling, Stella ^a   Fabian, Denise ^a   Manring, Isabel ^a   Jilg, Cordula A ^b   Schultze Seemann, Wolfgang ^b   McNulty, Maureen ^a   Zynger, Debra L ^c   Martin, Douglas ^a   White, Julia ^a   Werner, Martin ^b   Grosu, Anca L ^b   Chakravarti, Arnab ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 451; MICRORNA 601; PROSTATE SPECIFIC ANTIGEN; RNA; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; FOLLOW UP; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; MALE; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; SCORING SYSTEM; AGED; AREA UNDER THE CURVE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; TREATMENT FAILURE;

AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; DISEASE PROGRESSION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 84924347511     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118745     Document Type: Article

References (89)

1. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000; 164: 101-105. PMID: 10840432
2. Amling CL. Biochemical recurrence after localized treatment. Urol Clin North Am. 2006; 33: 147-159, v. PMID: 16631453
3. Botticella A, Guarneri A, Levra NG, Munoz F, Filippi AR, Rondi N, et al. Biochemical and clinical outcomes after high-dose salvage radiotherapy as monotherapy for prostate cancer. J Cancer Res Clin Oncol. 2014; 140: 1111-1116. doi: 10.1007/s00432-014-1673-8 PMID: 24744191
4. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006; 107: 2384-2391. PMID: 17039503
5. May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. J Urol. 2007; 178: 1957-1962; discussion 1962. PMID: 17868719
6. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005; 173: 1938-1942. PMID: 15879786
7. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007; 69: 1095-1101. PMID: 17572194
8. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001; 58: 843-848. PMID: 11744442
9. D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 2000; 55: 572-577. PMID: 10736506
10. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005; 23: 7005-7012. PMID: 16192588
11. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006; 98: 715-717. PMID: 16705126
12. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25: 2035-2041. PMID: 17513807
13. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Oncotype DX prostate cancer assay-A clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013; 14: 690. doi: 10.1186/1471-2164-14-690 PMID: 24103217
14. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013; 8: e66855. doi: 10.1371/journal.pone.0066855 PMID: 23826159
15. Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014; 89: 1038-1046. doi: 10.1016/j.ijrobp.2014.04.052 PMID: 25035207
16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105: 10513-10518. doi: 10.1073/pnas.0804549105 PMID: 18663219
17. Liu A, Xu X. MicroRNA isolation from formalin-fixed, paraffin-embedded tissues. Methods Mol Biol. 2011; 724: 259-267. doi: 10.1007/978-1-61779-055-3-16 PMID: 21370018
18. Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate Int. 2013; 1: 3-9. doi: 10.12954/PI.12011 PMID: 24223395
19. Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, et al. MiRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol. 2011; 39: 1183-1192. doi: 10.3892/ijo.2011.1128 PMID: 21769427
20. Larne O, Martens-Uzunova E, Hagman Z, Edsjo A, Lippolis G, den Berg MS, et al. miQ-A novel micro-RNA based diagnostic and prognostic tool for prostate cancer. Int J Cancer. 2013; 132: 2867-2875. doi: 10.1002/ijc.27973 PMID: 23184647
21. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012; 31: 978-991. doi: 10.1038/onc.2011.304 PMID: 21765474
22. Lichner Z, Fendler A, Saleh C, Nasser AN, Boles D, Al-Haddad S, et al. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem. 2013; 59: 1595-1603. doi: 10.1373/clinchem.2013.205450 PMID: 23958847
23. Long Q, Johnson BA, Osunkoya AO, Lai YH, Zhou W, Abramovitz M, et al. Protein-coding and micro-RNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol. 2011; 179: 46-54. doi: 10.1016/j.ajpath.2011.03.008 PMID: 21703393
24. Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, et al. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One. 2013; 8: e65064. doi: 10.1371/journal.pone.0065064 PMID: 23798998
25. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26: 317-325. doi: 10. 1038/nbt1385 PMID: 18278033
26. Reis PP, Waldron L, Goswami RS, Xu W, Xuan Y, Perez-Ordonez B, et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol. 2011; 11: 46. doi: 10. 1186/1472-6750-11-46 PMID: 21549012
27. Quek SI, Ho ME, Loprieno MA, Ellis WJ, Elliott N, Liu AY. A multiplex assay to measure RNA transcripts of prostate cancer in urine. PLoS One. 2012; 7: e45656. doi: 10.1371/journal.pone.0045656 PMID: 23029164
28. Nielsen T, Wallden B, Schaper C, Ferree S, Liu S, Gao D, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014; 14: 177. doi: 10. 1186/1471-2407-14-177 PMID: 24625003
29. Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP. AJCC Cancer Staging Manual Springer. 2009.
30. Sobin LH, Gospodarowicz MK, and Wittekind C. TNM Classification of Malignant Tumours: John Wiley & Sons. 2009.
31. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131.PMID: 17509297
32. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29: 1228-1242. PMID: 16096414
33. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10: R64. doi: 10. 1186/gb-2009-10-6-r64 PMID: 19531210
34. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30: 207-210. PMID: 11752295
35. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007; 177: 540-545. PMID: 17222629
36. Srivastava A, Goldberger H, Dimtchev A, Marian C, Soldin O, Li X, et al. Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol. 2014; 35: 4867-4873. doi: 10.1007/s13277-014-1638-1 PMID: 24477576
37. Mazeh H, Mizrahi I, Ilyayev N, Halle D, Brucher B, Bilchik A, et al. The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer-A Comprehensive review. J Cancer. 2013; 4: 281-295. doi: 10. 7150/jca.5836 PMID: 23459799
38. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013; 19: 3600-3610. doi: 10.1158/1078-0432.CCR-12-3092PMID: 23697990
39. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta. 2012; 1819: 1154- 1163. doi: 10.1016/j. bbagrm.2012.08.016 PMID: 22982408
40. Girardi C, De Pitta C, Casara S, Sales G, Lanfranchi G, Celotti L, et al. Analysis of MiRNA and mRNA expression profiles highlights alterations in ionizing radiation response of human lymphocytes under modeled microgravity. PLoS One. 2012; 7: e31293. doi: 10.1371/journal.pone.0031293 PMID: 22347458
41. Nygren MK, Tekle C, Ingebrigtsen VA, Makela R, Krohn M, Aure MR, et al. Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. Br J Cancer. 2014; 110: 2072-2080. doi: 10.1038/bjc.2014.113 PMID: 24577056
42. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009; 2: 963-970. doi: 10.3892/mmr-00000199 PMID: 21475928
43. Yang M, Liu R, Sheng J, Liao J, Wang Y, Pan E, et al. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep. 2013; 29: 169-176. doi: 10.3892/or.2012.2105 PMID: 23124769
44. Yang Y, Gu X, Zhou M, Xiang J, Chen Z. Serum microRNAs: A new diagnostic method for colorectal cancer. Biomed Rep. 2013; 1: 495-498. PMID: 24648974
45. Chowdhari S, Saini N. hsa-miR-4516 Mediated Downregulation of STAT3/CDK6/UBE2N Plays a Role in PUVA Induced Apoptosis in Keratinocytes. J Cell Physiol. 2014.
46. Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, et al. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 2013; 34: 530-538. doi: 10.1093/carcin/bgs371 PMID: 23188675
47. Chiavacci E, Rizzo M, Pitto L, Patella F, Evangelista M, Mariani L, et al. The zebrafish/tumor xenograft angiogenesis assay as a tool for screening anti-Angiogenic MiRNAs. Cytotechnology. 2014.
48. Gordanpour A, Nam RK, Sugar L, Seth A. MicroRNAs in prostate cancer: from biomarkers to molecular-ly-based therapeutics. Prostate Cancer Prostatic Dis. 2012; 15: 314-319. doi: 10.1038/pcan.2012.3PMID: 22333688
49. Liu X, Chen Z, Yu J, Xia J, Zhou X. MicroRNA profiling and head and neck cancer. Comp Funct Genomics. 2009: 837514.
50. Schaar DG, Medina DJ, Moore DF, Strair RK, Ting Y. miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol. 2009; 37: 245-255. doi: 10.1016/j.exphem.2008.10.002 PMID: 19135902
51. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, et al. Epigenetic silencing of Micro-RNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology. 2009; 9: 293-301. doi: 10.1159/000186051 PMID: 19407485
52. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14: 2348-2360. doi: 10.1261/rna.1034808 PMID: 18812439
53. Chen L, Yan HX, Yang W, Hu L, Yu LX, Liu Q, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 2009; 50: 358-369. doi: 10.1016/j.jhep.2008.09.015 PMID: 19070389
54. Gao W, Shen H, Liu L, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol. 2011; 137: 557-566. doi: 10.1007/s00432-010-0918-4 PMID: 20508945
55. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008; 68: 6416-6424. doi: 10.1158/ 0008-5472.CAN-07-6110 PMID: 18676867
56. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol. 2012; 14: 159-167. doi: 10.1038/ncb2396 PMID: 22179046
57. Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y, Huang RS. Genetic variation that predicts platinum sensitivity reveals the role of miR-193b∗in chemotherapeutic susceptibility. Mol Cancer Ther. 2012; 11: 2054-2061. doi: 10.1158/1535-7163.MCT-12-0221 PMID: 22752226
58. Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC, Hong TM. miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis. 2014; 17: 247-260. doi: 10.1007/s10456-013-9394-1 PMID: 24114198
59. Noto JM, Piazuelo MB, Chaturvedi R, Bartel CA, Thatcher EJ, Delgado A, et al. Strain-specific suppression of microRNA-320 by carcinogenic Helicobacter pylori promotes expression of the antiapoptotic protein Mcl-1. Am J Physiol Gastrointest Liver Physiol. 2013; 305: G786-796. doi: 10.1152/ajpgi. 00279.2013 PMID: 24136787
60. Blenkiron C, Hurley DG, Fitzgerald S, Print CG, Lasham A. Links between the oncoprotein YB-1 and small non-coding RNAs in breast cancer. PLoS One. 2013; 8: e80171. doi: 10.1371/journal.pone. 0080171 PMID: 24260353
61. Cheng C, Chen ZQ, Shi XT. MicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase. Tumour Biol. 2014; 35: 4177-4183. doi: 10.1007/s13277-013-1546-9 PMID: 24390663
62. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, et al. Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One. 2011; 6: e20341. doi: 10.1371/journal.pone.0020341 PMID: 21647377
63. Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014; 33: 3267-3276. doi: 10.1038/onc.2013. 297 PMID: 23893241
64. Liang S, Chen L, Huang H, Zhi D. The experimental study of MiRNA in pituitary adenomas. Turk Neurosurg. 2013; 23: 721-727. doi: 10.5137/1019-5149.JTN.7425-12.1 PMID: 24310454
65. Yan H, Wang S, Yu H, Zhu J, Chen C. Molecular pathways and functional analysis of MiRNA expression associated with paclitaxel-induced apoptosis in hepatocellular carcinoma cells. Pharmacology. 2013; 92: 167-174. doi: 10.1159/000354585 PMID: 24060847
66. Wang Z, Wang J, Yang Y, Hao B, Wang R, Li Y, et al. Loss of has-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer. J Exp Clin Cancer Res. 2013; 32: 76. doi: 10. 1186/1756-9966-32-76 PMID: 24422944
67. Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, et al. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biol. 2013; 34: 3501-3508. doi: 10.1007/ s13277-013-0928-3 PMID: 23836287
68. Zhai Q, Zhou L, Zhao C, Wan J, Yu Z, Guo X, et al. Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun. 2012; 419: 621-626. doi: 10.1016/j.bbrc.2012.02.060 PMID: 22369946
69. Dong L, Li Y, Han C, Wang X, She L, Zhang H. MiRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients. Int J Oncol. 2014; 45: 746-756. doi: 10.3892/ijo.2014.2459 PMID: 24858071
70. Mosakhani N, Guled M, Leen G, Calabuig-Farinas S, Niini T, Machado I, et al. An integrated analysis of MiRNA and gene copy numbers in xenografts of Ewing's sarcoma. J Exp Clin Cancer Res. 2012; 31:24 doi: 10.1186/1756-9966-31-24 PMID: 22429812
71. Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One. 2011; 6: e24248. doi: 10.1371/journal.pone.0024248 PMID: 21912681
72. Zhao BS, Liu SG, Wang TY, Ji YH, Qi B, Tao YP, et al. Screening of microRNA in patients with esophageal cancer at same tumor node metastasis stage with different prognoses. Asian Pac J Cancer Prev. 2013; 14: 139-143. PMID: 23534712
73. Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M, Enokida H. Aberrant expression of micro-RNAs in bladder cancer. Nat Rev Urol. 2013; 10: 396-404. doi: 10.1038/nrurol.2013.113 PMID: 23712207
74. Riaz M, van Jaarsveld MT, Hollestelle A, Prager-van der Smissen WJ, Heine AA, Boersma AW, et al. MiRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutationspecific MiRNAs. Breast Cancer Res. 2013; 15: R33. doi: 10.1186/bcr3415 PMID: 23601657
75. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential Urinary MiRNA Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients. J Cancer. 2014; 5: 182-191. doi: 10.7150/jca.6799 PMID: 24563673
76. Cao YX, Dai CW, Zhang GS. Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines. Zhonghua Xue Ye Xue Za Zhi. 2010; 31: 361-365. PMID: 21122348
77. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. Reprogramming of MiRNA networks in cancer and leukemia. Genome Res. 2010; 20: 589-599. doi: 10.1101/gr.098046. 109 PMID: 20439436
78. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56: 337-344. PMID: 10877287
79. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007; 27: 91-105. PMID: 17612493
80. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008; 36: D149-153. PMID: 18158296
81. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA Profiling of Prostate Cancer. J Cancer. 2013; 4: 350-357. doi: 10.7150/jca.6394 PMID: 23781281
82. Schaefer A, Jung M, Miller K, Lein M, Kristiansen G, Erbersdobler A, et al. Suitable reference genes for relative quantification of MiRNA expression in prostate cancer. Exp Mol Med. 2010; 42: 749-758. PMID: 20890088
83. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18: 11-22. doi: 10.1016/j.ccr.2010.05.026 PMID: 20579941
84. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, et al. Identification of MiRNAs associated with tumorigenesis of retinoblastoma by MiRNA microarray analysis. Childs Nerv Syst. 2009; 25: 13-20. doi: 10. 1007/s00381-008-0701-x PMID: 18818933
85. Corcoran C, Rani S, O'Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014; 74: 1320-1334. doi: 10.1002/pros.22848 PMID: 25053345
86. Ohdaira H, Nakagawa H, Yoshida K. Profiling of molecular pathways regulated by microRNA 601.Comput Biol Chem. 2009; 33: 429-433. doi: 10.1016/j.compbiolchem.2009.09.003 PMID: 19889580
87. Veuger SJ, Hunter JE, Durkacz BW. Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene. 2009; 28: 832-842. doi: 10.1038/onc.2008.439 PMID: 19060926
88. Magne N, Toillon RA, Bottero V, Didelot C, Houtte PV, Gerard JP, et al. NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett. 2006; 231: 158-168. PMID: 16399220
89. Fan Y, Mao R, Yang J. NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013; 4: 176-185. doi: 10.1007/s13238-013-2084-3 PMID: 23483479